ArticleCancer cell2014
Hematogenous metastasis of ovarian cancer: rethinking mode of spread.
Open access · greenAbstract read
In one paragraph
Article in Cancer cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers.
0numbers the graph read from it
0cells of the map it votes in
194citing papers in PubMed
29.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
194 citing papers in PubMed, 320 citations in OpenAlex.
- A randomized controlled trial to compare short-term outcomes following infragastric and infracolic omentectomy at the time of primary debulking surgery for epithelial ovarian cancer with normal-appearing omentum.Journal of ovarian research · 2024Trial
- Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer.Frontiers in immunology · 2021Trial
- Pre-operative circulating tumor cells predict worse treatment outcome in patients with high-grade serous ovarian cancer.Oncogene · 2026Article
- Circulating Lipid Traits and Ovarian Cancer Risk: A Systematic Review and Meta-Analysis with Mendelian Randomization Integration.Metabolites · 2026Review
- Ex Vivo Microfluidic Model Identifies a Role for Shear Stress during Ovarian Tumor Cell Attachment to Peritoneal Mesothelial Cells.ACS biomaterials science & engineering · 2026Article
- Loss of ErbB3 redirects Integrin β1 from early endosomal recycling to secretion in extracellular vesicles.The Journal of cell biology · 2026Article
- Diversity within ovarian cancer subtypes and their tumor microenvironment.Frontiers in oncology · 2026Review
- LAPTM5 drives omental metastasis in high-grade serous ovarian cancer via TGF-β/Smad-mediated epithelial plasticity.Journal of translational medicine · 2025Article
- Ovarian cancer metastasis to the human omentum disrupts organ homeostasis and induces fundamental tissue reprogramming.Nature communications · 2025Article
- Two Faces of Greater Omentum.Comprehensive physiology · 2025Review
- Biomimetic organo-hydrogels reveal the adipose tissue local mechanical anisotropy regulates ovarian cancer invasion.Nature communications · 2025Article
- Clinical implications of epithelial-to-mesenchymal transition in cancers which potentially spread to peritoneum.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Cystathionine gamma-lyase-mediated hypoxia inducible factor 1-alpha expression drives clear cell ovarian cancer progression.The Journal of pathology · 2025Article
- TLR Agonist Nano Immune Therapy Clears Peritoneal and Systemic Ovarian Cancer.Advanced healthcare materials · 2025Article
- The silent spread: exploring diverse metastatic pathways in high-grade serous ovarian cancer.Frontiers in medicine · 2025Review
- Characteristics and clinical significance of immune cells in omental milky spots of patients with gastric cancer.Frontiers in immunology · 2025Article
- Ovarian Carcinoma Initially-presented as Cerebral Metastasis: Epidemiology, Pathology, and Outcomes.Materia socio-medica · 2025Article
- HPV-YAP1 oncogenic alliance drives malignant transformation of fallopian tube epithelial cells.EMBO reports · 2024Article
- Unraveling the extracellular vesicle network: insights into ovarian cancer metastasis and chemoresistance.Molecular cancer · 2024Review
- Gastric Cancer Mesenchymal Stem Cells Trigger Endothelial Cell Functional Changes to Promote Cancer Progression.Stem cell reviews and reports · 2024Article
134 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 3 institutions in 2 countries.
Sunila PradeepDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Seung W KimDepartment of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Sherry Y WuDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Masato NishimuraDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Pradeep Chaluvally-RaghavanDepartment of Systems Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Takahito MiyakeDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Chad V PecotDepartment of Thoracic, Head, and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Sun-Jin KimDepartment of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Hyun Jin ChoiDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Farideh Z BischoffBiocept Inc., San Diego, CA 92121, USA.
Julie Ann MayerBiocept Inc., San Diego, CA 92121, USA.
Li HuangDepartment of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Alpa M NickDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Carolyn S HallDepartment of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Cristian Rodriguez-AguayoDepartment of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-coding RNA, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Behrouz ZandDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Heather J DaltonDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Thiruvengadam ArumugamDepartment of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Ho Jeong LeeDepartment of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Hee Dong HanDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-coding RNA, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Department of Immunology Laboratory, School of Medicine, Konkuk University, Chungju 380-701, South Korea.
Min Soon ChoDepartment of Benign Hematology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Rajesha RupaimooleDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Lingegowda S MangalaDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-coding RNA, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Vasudha SehgalDepartment of Systems Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Sang Cheul OhDepartment of Systems Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Division of Hemato-Oncology, Department of Internal Medicine, Korea University Medical Center, Korea University College of Medicine, Seoul 136-705, Korea.
Jinsong LiuDepartment of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Ju-Seog LeeDepartment of Systems Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Robert L ColemanDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Prahlad RamDepartment of Systems Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Gabriel Lopez-BeresteinDepartment of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-coding RNA, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Isaiah J FidlerDepartment of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-coding RNA, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: asood@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USBiopeptide (United States) · USKorea University Medical Center · KR
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MUPR/MDACC Partnership for Excellence in Cancer Research(Parent Grant U54 CA096297)U54CA096297 · NCI · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Ilka C Rios · 2002 to 2026
$36.9MUNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0MTargeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0MUPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Larkin Strong · 2002 to 2026
$23.8MTexas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2010 to 2014
$12.4MTraining of Academic Gynecologic OncologistsT32CA101642 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIL K SOOD, Kathleen Schmeler · 2005 to 2026
$9.2MOvarian Cancer: Mechanisms of Neuroendocrine RegulationR01CA109298 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2005 to 2017
$4.5MPlatelets promote growth of ovarian cancerR01CA177909 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AFSHAR-KHARGHAN, VAHID, SOOD, ANIL K · 2013 to 2023
$4.1MNovel extra cellular RNA-based combinatorial RNA inhibition therapyUH2TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2013 to 2014
$1.1MNCATS NIH HHS UH2 TR000943NCI NIH HHS CA109298NCI NIH HHS CA177909NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS P50CA083639NCI NIH HHS P50 CA098258NCI NIH HHS P50CA098258NCI NIH HHS R01 CA109298NCI NIH HHS R01 CA177909NCI NIH HHS T32 CA101642NCI NIH HHS U54 CA096297NCI NIH HHS U54 CA096300NCI NIH HHS U54 CA151668
Abstract
Ovarian cancer has a clear predilection for metastasis to the omentum, but the underlying mechanisms involved in ovarian cancer spread are not well understood. Here, we used a parabiosis model that demonstrates preferential hematogenous metastasis of ovarian cancer to the omentum. Our studies revealed that the ErbB3-neuregulin 1 (NRG1) axis is a dominant pathway responsible for hematogenous omental metastasis. Elevated levels of ErbB3 in ovarian cancer cells and NRG1 in the omentum allowed for tumor cell localization and growth in the omentum. Depletion of ErbB3 in ovarian cancer impaired omental metastasis. Our results highlight hematogenous metastasis as an important mode of ovarian cancer metastasis. These findings have implications for designing alternative strategies aimed at preventing and treating ovarian cancer metastasis.
Indexed as
AnimalsCarcinoma, Ovarian EpithelialCell Line, TumorCell MovementCell ProliferationFemaleHumansMiceMice, Inbred C57BLMice, NudeNeoplasm InvasivenessNeoplasms, Glandular and EpithelialNeoplastic Cells, CirculatingNeuregulin-1OmentumOvarian NeoplasmsERBB3 protein, humanNeuregulin-1NRG1 protein, humanReceptor, ErbB-3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.